LIBERTY ASTHMA QUEST

Dupilumab in Moderate-to-Severe Uncontrolled Asthma

Patient / Population Intervention / Exposure Comparison Outcome

In 1,902 patients with uncontrolled moderate-to-severe asthma, dupilumab 200 or 300 mg every 2 weeks reduced severe exacerbations and improved FEV1 compared with placebo.

1,902

Design

Multicentre phase-3 RCT

Endpoint

Co-primary: annualised severe exacerbation rate and change in FEV1 at week 12

Relevance

ResultSevere exacerbation rate reduced 47.7% (200 mg) / 46% (300 mg) vs placebo, both P<0.001; FEV1 placebo-adjusted +0.14 L at wk 12, P<0.001. Greater effect at higher baseline blood eosinophils.

Castro M, et al. N Engl J Med. 2018;378(26):2486-2496. 10.1056/NEJMoa1804092

Discussion & critique

Approved dupilumab for moderate-to-severe type-2 asthma.